Story March 27 - Lyndra Therapeutics: After spinning out from Moderna co-founder Robert Langer’s lab at the Massachusetts Institute of Technology ... stop work on a trial of its COVID-19 vaccine ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, ...

A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, a technology that allows genes to be manipulated inside the body. The two companies claim AGN ...

The company said on Monday that a second phase 3 trial “did not meet its primary endpoint” after disappointing investors only last week with the news that a first phase 3 trial had failed.

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial in humans ... than current PD-1–targeted drugs as the technology directly knocks-out the gene ...

The study was a randomised (3:2), double-blind control procedure US trial, stratified by clinical site and cardiac resynchronization therapy (CRT) and focused on patients whose cells met ...

As numerous reports have documented, most large companies are — as one would expect — spending more on technology each year. Does it follow, then, that their spending on technology training is ...

“Some knowledge of technology and operating smartphones is needed for availing that option,” he added, responding to whether people from lower economic backgrounds use telemedicine. He ...

Social media giants Meta and Snapchat are among the 51 tech companies who have signed on to be part of the $6.5m world-leading trial commissioned by the federal government. The Age Assurance ...